• Skip to main content
  • Skip to footer

Qu Biologics

  • Who We Are
    • Mission and Values
    • Team and Board
  • What We Do
    • Transformational Science
    • SSI Platform
    • SSI Pipeline
    • Publications
  • Current Clinical Trials
    • RESILIENCE Study
    • PERIOP-06 Study
  • News
    • In the Press
    • Events
  • Investors
  • Careers
  • Contact
Search
Close Search
Resilience Web Lead Photo Banner
Asian Senior Couple In Love Laughing.

RESILIENCE Study

Now recruiting: 65 years of age or older

Are you 65 years of age or older and interested in participating in a clinical study evaluating a new immunomodulator designed to enhance your natural immunity?

What is the RESILIENCE Study about?

As we age, our immune function declines, leaving us more susceptible to decline in health and the development of diseases including cancer, infections, and chronic inflammatory diseases. This was apparent in the COVID-19 pandemic, in which older adults suffered disproportionally.

The RESILIENCE Study is evaluating a new immunomodulator designed to improve natural immune function and health in adults 65 years of age or older.

What is the Study evaluating?

Just like our muscles, our innate immune system benefits from training. Our immune system relies on beneficial exposure to bacteria for this training, making our innate immune system stronger and more resilient.

The RESILIENCE Study is evaluating an immunomodulator, made from inactivated bacteria, designed to train the immune system and reverse the decline in innate immunity that occurs with aging to maintain health and reduce the risk of infections, cancer, and chronic inflammatory diseases.

What does the Study involve?

  • Study treatment period of 28 days
  • Immune monitoring for an additional 5 months (blood will be collected 5 times)
  • Regular interactions and support from clinical study staff

Who can participate?

You may be eligible to participate if you are:

  • 65 years of age or older
  • Living in the Greater Vancouver Area

Who is conducting the Study?

Ted Steiner 4x3Dr. Theodore Steiner, Professor of Medicine at University of British Columbia, Infectious Diseases Specialist at Vancouver General Hospital, Research Scientist at BC Children’s Hospital Research Institute, and Chief Medical Officer for Infectious Diseases at Qu Biologics, is the Principal Investigator of the Study.

Collaborators

Ubc Logo 2018 Crest Blue Rgb72                 Vchri Logo Rgb Transparent      Logoprovidencehealthcare Qu Biologics Logo

This Study is a collaboration between Qu Biologics, the University of British Columbia, Vancouver Coastal Health Research Institute, and Providence Health Care. This Study is supported by the Canadian government through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

If you would like to learn more about this Study, please contact the RESILIENCE Study team who will be pleased to discuss the Study and answer your questions

Phone: (877) 223-8637                Email: info@isstudy.ca

For more information about the design of the Study, Click Here

Contact Us

Interested in learning more about the RESILIENCE Study? Please fill out the form below, and a member of our study team will be in touch shortly.
Please enable JavaScript in your browser to complete this form.
Name
Preferred Contact Method
Loading
Logo Light
  • Who We Are
  • What We Do
  • Current Clinical Trials
  • News
  • Investors
  • Careers
  • Contact
  • 4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4
  • 604.734.1450
    info@qubiologics.com

dashicons-facebook-alt
dashicons-twitter
dashicons-linkedin
dashicons-youtube

© 2025 Qu Biologics Inc. All Rights Reserved
| Terms of Use | Privacy Policy